OccuLogix, Inc.

OccuLogix, Inc.

October 05, 2005 07:55 ET

OccuLogix, Inc.: Accomplished Industry Veteran, Steve Parks, Joins OccuLogix as Vice President of Sales

TORONTO, ONTARIO--(CCNMatthews - Oct. 5, 2005) - OccuLogix, Inc. (NASDAQ:RHEO)(TSX:RHE) announced today the appointment of Steve Parks as the company's Vice President of Sales. Mr. Parks succeeds Joseph Zawaideh who will remain with the company in a sales and business development capacity.

Mr. Parks has an accomplished history of medical device sales and sales management success within the ophthalmic industry. He joins OccuLogix from his current position as Vice President, Sales at Advanced Medical Optics, Inc. (NYSE:EYE), a Santa Ana, CA based global leader in ophthalmic surgical devices and eye care products.

Before joining Advanced Medical Optics upon its acquisition of VISX, Inc., in May 2005, Mr. Parks led VISX's excimer laser sales and procedure fee business in the eastern part of the United States from 1995 to 2005. Prior to joining VISX, Mr. Parks held a variety of sales and sales management positions with Alcon Surgical, Coopervision Surgical Systems, Johnson & Johnson (NYSE:JNJ) and Procter & Gamble Co. (NYSE:PG).

"We are very pleased to have attracted a sales leader of Steve Parks' caliber to this key position. His extensive and demonstrable record of accomplishment in rolling out new medical devices and procedures to ophthalmology will be a great asset for OccuLogix going forward," commented Tom Reeves, OccuLogix's President and COO.

Steve Parks said, "Prior to FDA approval of the excimer laser in the mid-90s, the laser vision correction procedure was viewed with some skepticism in the United States. After FDA approval, however, doctor education combined with excellent clinical outcomes quickly drove awareness and acceptance of LASIK to the point that it soon exploded in popularity to become the world's most widely performed elective surgical procedure. Indeed, refractive surgery is now often described as the second wave of ophthalmology, behind modern cataract surgery. I am convinced that the RHEO™ procedure for Dry AMD has the potential of becoming the third wave. I'm very excited to have the opportunity to contribute to another paradigm shift in ophthalmology."

About OccuLogix, Inc.

OccuLogix is a health care company that brings innovative and evidenced-based medical therapies to market. OccuLogix's common shares trade on the NASDAQ National Market under the symbol 'RHEO' and on the Toronto Stock Exchange under the symbol 'RHE'. Visit us on the internet at www.occulogix.com (corporate) and www.rheo.com (healthcare professionals, patients and caregivers).

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian regulatory authorities, including, but not limited to, our Registration Statement on Form S-1 and our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

Contact Information